Article

Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients: a prospective, randomized, multicenter trial.

Infectious Disease Sections, Veterans Affairs Medical Center and University of Pittsburgh, PA, USA.
Archives of Internal Medicine (Impact Factor: 11.46). 05/2000; 160(9):1294-300. DOI: 10.1001/archinte.160.9.1294
Source: PubMed

ABSTRACT To compare the efficacy and safety of azithromycin dihydrate monotherapy with those of a combination of cefuroxime axetil plus erythromycin as empirical therapy for community-acquired pneumonia in hospitalized patients.
Patients were enrolled in a prospective, randomized, multicenter study. The standard therapy of cefuroxime plus erythromycin was consistent with the American Thoracic Society, Canadian Community-Acquired Pneumonia Consensus Group, and Infectious Disease Society of America consensus guidelines. The doses were intravenous azithromycin (500 mg once daily) followed by oral azithromycin (500 mg once daily), intravenous cefuroxime (750 mg every 8 hours), followed by oral cefuroxime axetil (500 mg twice daily), and erythromycin (500-1000 mg) intravenously or orally every 6 hours. Randomization was stratified by severity of illness and age. Patients who were immunosuppressed or residing in nursing homes were excluded.
Data from 145 patients (67 received azithromycin and 78 received cefuroxime plus erythromycin) were evaluable. Streptococcus pneumoniae and Haemophilus influenzae were isolated in 19% (28/145) and 13% (19/145), respectively. The atypical pathogens accounted for 33% (48/145) of the etiologic diagnoses; Legionella pneumophila, Chlamydia pneumoniae, and Mycoplasma pneumoniae were identified in 14% (20/ 145), 10% (15/145), and 9% (13/145), respectively. Clinical cure was achieved in 91% (61/67) of the patients in the azithromycin group and 91% (71/78) in the cefuroxime plus erythromycin group. Adverse events (intravenous catheter site reactions, gastrointestinal tract disturbances) were significantly more common in patients who received cefuroxime plus erythromycin (49% [30/78]) than in patients who received azithromycin (12% [8/67]) (P<.001).
Treatment with azithromycin was as effective as cefuroxime plus erythromycin in the empirical management of community-acquired pneumonia in immunocompetent patients who were hospitalized. Azithromycin was well tolerated.

0 Bookmarks
 · 
189 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Patients with community-acquired pneumonia (CAP) are treated in hospital or in the ambulatory care setting depending on the severity of illness. Despite numerous guidelines proposed, there is no agreement on specific criteria for hospitalization other than the clinicians’ experience. The purpose of this review is to discuss the importance of the appropriate choice and timely administration of antibacterial agents, either in the hospital or in the outpatient setting. Since a high proportion of CAP patients will not have an etiologic agent identified at the time of initiation of treatment, the choice of antibacterial therapy is usually empiric. Antibacterial agents with activity against pneumococci and atypical pathogens causing pneumonia are the preferred choices. Macrolides, doxycycline, or respiratory fluoroquinolones have been recommended by various guidelines committees in North America for the treatment of pneumonia in patients with or without underlying comorbidities. Because of the increasing resistance to β-lactams as well other antibacterial agents such as macrolides, doxycycline, and sulfamethoxazole/trimethoprim (cotrimoxazole), it is important that clinicians are aware of local statistics on resistance to Streptococcus pneumoniae, as infection with this bacterium is associated with high rates of morbidity and mortality. More recently, fluoroquinolone resistance has been reported, but the percentage of pneumococcal strains resistant to this agent is relatively low compared with the other antibacterial agents. Switch (intravenous to oral) therapy is recommended for hospitalized patients with CAP to facilitate early discharge, which has been shown to improve patient satisfaction and reduce hospital costs. Early conversion to oral therapy has not been shown to be associated with increased complications or higher mortality. Following prompt intravenous therapy and stabilization, patients with CAP should be treated with oral therapy in the ambulatory setting.
    American journal of respiratory medicine: drugs, devices, and other interventions 10/2012; 2(5).
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Community-acquired pneumonia (CAP) is a serious and widespread infection due to its high incidence, morbidity, mortality and increased healthcare costs. This study aimed at investigating antibiotic combination regimen containing fluoroquinolone (Group A) and antibiotic combination regimen not containing fluoroquinolone (Group B) in terms of effectiveness parameters and direct medical costs associated with treatment of CAP patients admitted to Intensive Care Unit (ICU). This study was designed as retrospective and prospective observational studies including CAP patients admitted to the Respiratory ICU. The patients’ files were collected and the effectiveness parameters of outcomes were compared on admission and on discharge. Effectiveness and costs analyses between antibiotic regimens either containing or not containing fluoroquinolone were performed. A total of 16 patients were enrolled in our retrospective study; (Group A) included 7 patients, while (Group B) included 9 patients. The prospective study included 30 patients; (Group A) included 13 patients and (Group B) included 17 patients. There was non-significant difference in the number of days in ICU between the two groups with a trend to shorter length of stay in ICU in (Group B) compared to (Group A) in both retrospective and prospective studies. Cost analysis showed that there was non-significant difference with a trend to lower direct medical costs in (Group B) which resulted in cost savings of (L.E) 1277 and (L.E) 816 for retrospective study and prospective study respectively. In conclusion, regimens containing or not containing fluoroquinolone did not show a significant increase in either effectiveness or costs of CAP treatment in the ICU.
    Bulletin of Faculty of Pharmacy, Cairo University. 06/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cefuroxime axetil, a prodrug of the cephalosporin cefuroxime, has proven in vitro antibacterial activity against several Gram-positive and Gram-negative organisms, including those most frequently associated with various common community-acquired infections. Antibacterial Activity Cefuroxime axetil, a cephalosporin antibacterial agent, prevents bacterial growth primarily by inhibiting penicillin-binding protein 3, resulting in bacterial elongation and leakage and, eventually, cell death. The drug shows good activity against a broad range of Gram-positive and Gram-negative bacteria in vitro, including those most commonly associated with respiratory tract infections [e.g. Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, S. pyogenes and methicillin-sensitive Staphylococcus aureus (MSSA)]. Pharmacokinetic Properties The lipophilic acetoxyethyl-ester prodrug cefuroxime axetil is well absorbed from the gastrointestinal tract and is rapidly hydrolysed by nonspecific esterases in the intestinal mucosa and blood to cefuroxime and the ester group. Therapeutic Efficacy Upper respiratory tract infections: In adult and adolescent patients with acute sinusitis, randomised controlled trials have shown that cefuroxime axetil (250mg twice daily for 8 to 10 days) provided comparable clinical and bacteriological efficacy to that of 7 to 10 days’ treatment with a quinolone agent, including moxifloxacin, gemifloxacin, sparfloxacin and ciprofloxacin. In clinically evaluable patients, satisfactory clinical responses occurred in 83 to 90% of cefuroxime axetil recipients versus 83 to 97% of patients receiving a quinolone comparator agent. Overall presumed or documented bacteriological eradication paralleled satisfactory clinical response rates, with eradication occurring in 89 to 95% of microbiologically evaluable cefuroxime axetil recipients versus 94 to 97% of those receiving a quinolone. Cefuroxime axetil also provided comparable clinical efficacy to that of clarithromycin or amoxicillin/clavulanic acid as assessed by clinical and bacteriological criteria. Furthermore, clinical (85 vs 87% of patients) and bacteriological response rates (89 vs 91%) indicated that 5 days’ treatment with cefuroxime axetil (250mg twice daily) was as effective as 10 days’ treatment in a double-blind trial. Pharmacoeconomic Considerations Pharmacoeconomic analyses of cefuroxime axetil have generally considered costs associated with treatment only from an institutional perspective. Indirect and societal costs have not been assessed to date. Tolerability Oral cefuroxime axetil 250mg or 500mg twice daily for 5 to 10 days was generally well tolerated in children and adults with various bacterial infections. The majority of adverse events were mild to moderate in intensity and reversible upon discontinuation of treatment, with very few serious adverse events reported. Less than 1 to 6% of patients withdrew because of adverse events attributable to cefuroxime axetil treatment. Dosage and Administration For adults and children aged ≥13 years with mild to moderate upper and lower respiratory tract infections caused by susceptible bacteria, the usual effective dose of cefuroxime axetil is 250mg twice daily for 7 to 10 days. To optimise absorption, cefuroxime axetil should be administered with food. The treatment of severe lower respiratory tract infections, including CAP, requires a higher dosage of cefuroxime axetil (usually 500mg twice daily). Currently, in the US prescribing information there are no dosage recommendations available for the use of intravenous cefuroxime/oral cefuroxime axetil sequential therapy. In the UK, in patients with AECB the recommended dosages for sequential therapy are intravenous or intramuscular cefuroxime 750mg twice daily for 2 to 3 days followed by oral cefuroxime axetil 500mg twice daily for 7 days; in patients with CAP, the recommended dosage of parenteral cefuroxime is 1.5g twice daily for 2 to 3 days, followed by cefuroxime axetil 500mg for 7 days.
    Drugs 61(10). · 4.13 Impact Factor

Full-text (2 Sources)

Download
113 Downloads
Available from
May 15, 2014